Market Closed -
Nyse
21:10:00 26/04/2024 BST
|
5-day change
|
1st Jan Change
|
0.8711
USD
|
-3.21%
|
|
-12.89%
|
-16.24%
|
Fiscal Period: September |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
109.8
|
104.2
|
120.2
|
13.63
|
2.958
|
2.653
|
-
|
Enterprise Value (EV)
1 |
109.8
|
89.71
|
93.93
|
13.63
|
2.958
|
2.653
|
2.653
|
P/E ratio
|
-1.4
x
|
7.14
x
|
-4.43
x
|
-0.18
x
|
-0.08
x
|
-0.4
x
|
-1.81
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
4.64
x
|
2.49
x
|
2.7
x
|
-
|
0.12
x
|
0.12
x
|
0.1
x
|
EV / Revenue
|
4.64
x
|
2.49
x
|
2.7
x
|
-
|
0.12
x
|
0.12
x
|
0.1
x
|
EV / EBITDA
|
-9,110,662
x
|
-6,180,573
x
|
-6,461,579
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-8,695,554
x
|
-8,325,074
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
616
|
1,158
|
1,284
|
1,346
|
2,858
|
3,045
|
-
|
Reference price
2 |
178.2
|
90.00
|
93.60
|
10.13
|
1.035
|
0.8711
|
0.8711
|
Announcement Date
|
18/12/19
|
22/12/20
|
17/12/21
|
15/12/22
|
22/12/23
|
-
|
-
|
Fiscal Period: September |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
23.65
|
41.88
|
44.48
|
-
|
24.16
|
22.51
|
27.02
|
EBITDA
|
-12.05
|
-16.86
|
-18.6
|
-
|
-
|
-
|
-
|
EBIT
1 |
-14.8
|
-17.58
|
-19.62
|
-
|
-5.527
|
-4.707
|
-2.517
|
Operating Margin
|
-62.56%
|
-41.98%
|
-44.1%
|
-
|
-22.88%
|
-20.91%
|
-9.32%
|
Earnings before Tax (EBT)
1 |
-47.79
|
11.31
|
-24.29
|
-
|
-22.94
|
-4.637
|
-2.517
|
Net income
1 |
-50.43
|
12.24
|
-25.95
|
-70.08
|
-26.94
|
-6.639
|
-2.517
|
Net margin
|
-213.21%
|
29.21%
|
-58.34%
|
-
|
-111.53%
|
-29.49%
|
-9.32%
|
EPS
2 |
-126.9
|
12.60
|
-21.15
|
-55.80
|
-13.32
|
-2.180
|
-0.4800
|
Free Cash Flow
|
-
|
-11.98
|
-14.44
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-28.61%
|
-32.45%
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
18/12/19
|
22/12/20
|
17/12/21
|
15/12/22
|
22/12/23
|
-
|
-
|
Fiscal Period: September |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2023 Q1
|
2023 Q2
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
9.793
|
9.322
|
-
|
8.593
|
-
|
-
|
5.711
|
5.375
|
5.403
|
5.714
|
6.022
|
EBITDA
|
-6.715
|
-4.729
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-7.013
|
-25.15
|
-
|
-
|
-
|
-
|
-0.5721
|
-1.066
|
-1.297
|
-1.2
|
-1.144
|
Operating Margin
|
-71.61%
|
-269.74%
|
-
|
-
|
-
|
-
|
-10.02%
|
-19.83%
|
-24.01%
|
-21%
|
-19%
|
Earnings before Tax (EBT)
1 |
-3.156
|
-19.16
|
-
|
-
|
-
|
-
|
-15.87
|
-0.9965
|
-1.297
|
-1.2
|
-1.144
|
Net income
1 |
-4.36
|
-20.16
|
-4.657
|
-
|
-
|
-1.77
|
-16.88
|
-1.997
|
-2.298
|
-1.2
|
-1.144
|
Net margin
|
-44.52%
|
-216.28%
|
-
|
-
|
-
|
-
|
-295.5%
|
-37.15%
|
-42.53%
|
-21%
|
-19%
|
EPS
2 |
-1.800
|
-15.75
|
-4.500
|
-24.75
|
-3.600
|
-1.160
|
-9.060
|
-0.6700
|
-0.7500
|
-0.3900
|
-0.3600
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
17/12/21
|
10/02/22
|
13/05/22
|
11/08/22
|
13/02/23
|
10/08/23
|
22/12/23
|
13/02/24
|
-
|
-
|
-
|
Fiscal Period: September |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
14.5
|
26.2
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-12
|
-14.4
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
1.2
|
1.32
|
0.34
|
-
|
0.3
|
-
|
-
|
Capex / Sales
|
5.07%
|
3.15%
|
0.77%
|
-
|
1.23%
|
-
|
-
|
Announcement Date
|
18/12/19
|
22/12/20
|
17/12/21
|
15/12/22
|
22/12/23
|
-
|
-
|
Last Close Price
0.8711
USD Average target price
2
USD Spread / Average Target +129.59% Consensus |
1st Jan change
|
Capi.
|
---|
| -16.24% | 2.65M | | +25.83% | 661B | | +27.00% | 566B | | -6.76% | 352B | | +20.34% | 332B | | +3.00% | 283B | | +13.09% | 231B | | +5.46% | 200B | | -9.61% | 195B | | -6.26% | 145B |
Other Pharmaceuticals
|